Chloroprocaine antagonizes progression of breast cancer by regulating LINC00494/miR‐3619‐5p/MED19 axis
Journal of Biochemical and Molecular Toxicology · 2024
DOI: 10.1002/jbt.23524 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2024. Verfasst von Chen Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, The First Affifiliated Hospital of Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Breast Neoplasms, MicroRNAs. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Basic and Clinical Cooperative Research Promotion Program of Anhui Medical University, Research Fund Project of Anhui Medical University, Open Research fund of Key Laboratory of Anesthesiology and Perioperative Medicine of Anhui Higher Education Institutes, Anhui Medical University.
Abstract (Originalsprache)
Breast cancer, as the most prevalent female malignancy, leads the cancer‐related death in women worldwide. Local anesthetic chloroprocaine exhibits antitumor potential, but its specific functions and underlying molecular mechanisms in breast cancer remain unclear. Here, we demonstrated chloroprocaine significantly inhibited proliferation, invasion and induced apoptosis of breast cancer cells in vitro. Tumor growth and pulmonary metastasis were also suppressed in BABL/c nude mice model with chloroprocaine treatment. LINC00494 was identified as one of the most downregulated long noncoding RNAs in chloroprocaine‐treated breast cancer cells by high‐throughput sequencing. Futhermore, high level of LINC00494 was positively associated with poor outcome of breast cancer patients. LINC00494 acted as a “miRNAs sponge” to compete with MED19 for the biding of miR‐3619‐5p, led to the upregulation of MED19. LINC00494/miR‐3619‐5p/MED19 axis participated in chloroprocaine‐mediated inhibition of proliferation, invasion and promotion of apoptosis of breast cancer cells. Consequently, our finding suggested local anesthetic chloroprocaine attenuated breast cancer aggressiveness through LINC00494‐mediated signaling pathway, which detailly revealed the clinical value of chloroprocaine during breast cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, The First Affifiliated Hospital of Anhui Medical University, Hefei, China.
- Anhui Public Health Clinical Center, Hefei, China.
- Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
- Key Laboratory of Anesthesiology and Perioperative Medicine of Anhui Higher Education Institutes, Anhui Medical University, Hefei, Anhui, China.
Förderung
- Basic and Clinical Cooperative Research Promotion Program of Anhui Medical University
- Research Fund Project of Anhui Medical University
- Open Research fund of Key Laboratory of Anesthesiology and Perioperative Medicine of Anhui Higher Education Institutes, Anhui Medical University
- Anhui Medical University
Zitieren
APA
Chen, C., Wang, N., Huang, T., Cheng, G., Hu, Y., Wang, B., Zhang, Y., & Wang, C. (2024). Chloroprocaine antagonizes progression of breast cancer by regulating LINC00494/miR‐3619‐5p/MED19 axis. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.23524
Vancouver
Chen C, Wang N, Huang T, Cheng G, Hu Y, Wang B, et al. Chloroprocaine antagonizes progression of breast cancer by regulating LINC00494/miR‐3619‐5p/MED19 axis. Journal of Biochemical and Molecular Toxicology. 2024. doi:10.1002/jbt.23524
BibTeX
@article{Chen2024,
author = {Chen, Chen and Wang, Ning and Huang, Tingting and Cheng, Gao and Hu, Yuexia and Wang, Bingjie and Zhang, Ye and Wang, Chunhui},
title = {Chloroprocaine antagonizes progression of breast cancer by regulating LINC00494/miR‐3619‐5p/MED19 axis},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2024},
doi = {10.1002/jbt.23524}
}
EUVIMED